7.0675
0.2375 (3.48%)
0.2375 (3.48%)
Upgrade to Real-Time
Regular Market
Volume | 88,621 |
|
|||||
News | - | ||||||
Day High | 7.25 | Low High |
|||||
Day Low | 6.83 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BriaCell Therapeutics Corporation | BCTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.83 | 6.83 | 7.25 | 6.83 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
631 | 88,621 | $ 7.04 | $ 624,324 | - | 4.06 - 12.09 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:40:46 | 1 | $ 7.075 | USD |
BriaCell Therapeutics Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 109.67M | 15.52M | 13.38M | $ - | $ - | -3.38 | -4.70 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 52.53k | - |
BriaCell Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.53 | 7.82 | 6.745 | 7.25 | 179,061 | -0.4625 | -6.14% |
1 Month | 5.43 | 7.82 | 5.30 | 6.89 | 271,008 | 1.64 | 30.16% |
3 Months | 5.95 | 7.82 | 4.23 | 6.01 | 214,411 | 1.12 | 18.78% |
6 Months | 6.56 | 8.37 | 4.23 | 6.38 | 319,837 | 0.5075 | 7.74% |
1 Year | 6.23 | 12.09 | 4.06 | 7.40 | 461,396 | 0.8375 | 13.44% |
3 Years | 4.24 | 12.47 | 2.8149 | 6.65 | 1,383,814 | 2.83 | 66.69% |
5 Years | 4.24 | 12.47 | 2.8149 | 6.65 | 1,383,814 | 2.83 | 66.69% |
BriaCell Therapeutics Description
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell is conducting a Phase II clinical trial of Bria-IMT in metastatic advanced breast cancer (Fast Track designation from FDA). BriaCell is developing Bria-OTS, a personalized off the shelf immunotherapy for cancer based on matching the patient's HLA type. Enhanced cellular immunotherapies with enhanced potency are under development. |